Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Association of low baseline levels of erythrocyte folate with treatment nonresponse at three months in rheumatoid arthritis patients receiving methotrexate.
de Rotte MC, de Jong PH, Pluijm SM, Calasan MB, Barendregt PJ, van Zeben D, van der Lubbe PA, de Sonnaville PB, Lindemans J, Hazes JM, de Jonge R. de Rotte MC, et al. Among authors: van zeben d. Arthritis Rheum. 2013 Nov;65(11):2803-13. doi: 10.1002/art.38113. Arthritis Rheum. 2013. PMID: 24166792 Free article. Clinical Trial.
Best cost-effectiveness and worker productivity with initial triple DMARD therapy compared with methotrexate monotherapy in early rheumatoid arthritis: cost-utility analysis of the tREACH trial.
de Jong PH, Hazes JM, Buisman LR, Barendregt PJ, van Zeben D, van der Lubbe PA, Gerards AH, de Jager MH, de Sonnaville PB, Grillet BA, Luime JJ, Weel AE. de Jong PH, et al. Among authors: van zeben d. Rheumatology (Oxford). 2016 Dec;55(12):2138-2147. doi: 10.1093/rheumatology/kew321. Epub 2016 Aug 30. Rheumatology (Oxford). 2016. PMID: 27581208 Clinical Trial.
Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial.
de Jong PH, Hazes JM, Barendregt PJ, Huisman M, van Zeben D, van der Lubbe PA, Gerards AH, de Jager MH, de Sonnaville PB, Grillet BA, Luime JJ, Weel AE. de Jong PH, et al. Among authors: van der lubbe pa, van zeben d. Ann Rheum Dis. 2013 Jan;72(1):72-8. doi: 10.1136/annrheumdis-2011-201162. Epub 2012 Jun 7. Ann Rheum Dis. 2013. PMID: 22679301 Clinical Trial.
Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis.
van den Hout WB, Goekoop-Ruiterman YP, Allaart CF, de Vries-Bouwstra JK, Hazes JM, Kerstens PJ, van Zeben D, Hulsmans HM, de Jonge-Bok JM, de Sonnaville PB, Dijkmans BA, Breedveld FC. van den Hout WB, et al. Among authors: van zeben d. Arthritis Rheum. 2009 Mar 15;61(3):291-9. doi: 10.1002/art.24169. Arthritis Rheum. 2009. PMID: 19248130 Free article. Clinical Trial.
Treatment decisions and related costs differ significantly depending on the choice of a disease activity index in RA, according to 1987 and 2010 classification criteria.
de Jong PH, Hazes JM, van Zeben D, van der Lubbe PA, de Jager MH, de Sonnaville PB, Luime JJ, Weel AE. de Jong PH, et al. Among authors: van der lubbe pa, van zeben d. Rheumatology (Oxford). 2012 Jul;51(7):1269-77. doi: 10.1093/rheumatology/kes008. Epub 2012 Feb 29. Rheumatology (Oxford). 2012. PMID: 22378716 Clinical Trial.
44 results